电话:
400-7060-959
传真:
+86 10 56315212-8813
电子邮件:
orders@antibodies-online.cn

Recombinant TNFSF11 (Denosumab Biosimilar) 抗体

适用: 人 FACS, in vivo 宿主: 小鼠 Monoclonal unconjugated Recombinant Antibody
产品编号 ABIN7200656
发货至: 中国
  • 抗原 See all TNFSF11 (Denosumab Biosimilar) products
    TNFSF11 (Denosumab Biosimilar)
    抗体类型
    Recombinant Antibody
    适用
    宿主
    • 1
    • 1
    小鼠
    克隆类型
    • 2
    单克隆
    标记
    • 2
    This TNFSF11 (Denosumab Biosimilar) antibody is un-conjugated
    应用范围
    Flow Cytometry (FACS), In vivo Studies (in vivo)
    原理
    Denosumab Biosimilar, Human RANKL Monoclonal Antibody
    特异性
    The monoclonal antibody denosumab biosimilar specifically binds to the human RANKL (RANK ligand) protein.
    产品特性
    Recombinant Humanized IgG2 Monoclonal Antibody.
    纯化方法
    Protein A affinity column
    纯度
    > 95% by SDS-PAGE under reducing conditions and HPLC.
    过滤
    0.2 μm filtered
    内毒素水平
    < 1 EU per 1 mg of the protein by the LAL method.
    免疫原
    The monoclonal antibody denosumab biosimilar was produced in the denosumab biosimilar CHO stable cell line.
    亚型
    IgG2 kappa
  • 应用备注
    ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by denosumab.
    限制
    仅限研究用
  • 状态
    Liquid
    浓度
    1 mg/mL
    缓冲液
    PBS, pH 7.4, no stabilizers or preservatives.
    储存液
    Without preservative
    注意事项
    Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
    储存条件
    -20 °C
    储存方法
    12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
    有效期
    12 months
  • 抗原
    TNFSF11 (Denosumab Biosimilar)
    Abstract
    TNFSF11 (Denosumab Biosimilar) 产品
    别名
    CD254 antibody, ODF antibody, OPGL antibody, OPTB2 antibody, RANKL antibody, TRANCE antibody, hRANKL2 antibody, sOdf antibody, TNF superfamily member 11 antibody, TNFSF11 antibody
    物质类
    Biosimilar
    背景
    Denosumab, a fully human monoclonal antibody, inhibits the RANKL (RANK ligand) protein, the primary signal for bone removal. Denosumab can be used for the treatment of osteoporosis, treatment-induced bone loss, bone metastases, multiple myeloma, and giant cell tumor of bone.
You are here: